BioSpace News Archive

Decipher Biosciences announced the appointments of Robert S. Epstein, M.D., and Kathy Hibbs, Esq. to its Board of Directors. Dr. Epstein was also elected Chairman of the Board.

Moderna, Inc. announced the pricing of an underwritten public offering of 26,315,790 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions.

The Annual General Meeting on October 30 resolved to extend the company’s financial year to the following period, July 1, 2019 - December 31, 2020.

Lysogene announced its participation to the upcoming 16th WORLDSymposium™ on Lysosomal Diseases to be held February 10 – 13, 2020 in Orlando, FL, USA.

Carbiotix announces that the company has launched its second generation diagnostic platform for gut health based on Next Generation Sequencing.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Aelian Biotechnology announced the signing of a license agreement granting Aelian access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to support Aelian’s commercial functional genomic screening platform.

Preclinical models demonstrate robust remyelinating activity, functional myelin generation, and improved motor function

Da Volterra announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluating DAV132 in patients receiving fluoroquinolone antibiotics.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2019.

FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)(1)